As shown in Figures 4(e)–4(h), in TNBC, the prognosis of tumors that were both resistin-positive and strongly EGFR-positive, or strongly resistin-positive and strongly EGFR-positive, did not differ significantly from that of other breast cancer groups. This evidence concerns the gene RETN and breast cancer.